RESUMEN
Prussian blue analogs (PBAs) are versatile materials with a wide range of applications. Due to their tunability, intrinsic biocompatibility, as well as low toxicity, these nanoscale coordination polymers have been successfully studied as multimodal contrast agents for multiple imaging techniques. Herein, we report the expanded biomedical application of PBAs to X-ray computed tomography (CT). In our systematic study of the series A{MnII[FeIII(CN)6]} (A = K+, Rb+, Cs+), we showed that derivatives incorporating Rb+ and Cs+ ions in the tetrahedral sites of the parent face-centered cubic cyano-bridged networks exhibited substantially increased X-ray attenuation coefficients, thus yielding significant contrast compared to the clinically approved X-ray contrast agent iohexol at the same concentrations. Additionally, our µ-CT studies revealed that these PBAs could be useful as dual-energy CT contrast agents for different biological specimens by using the lower varying scanning X-ray tube voltages. Finally, in vitro studies using U87-Luc cells treated with PBAs, including cellular CT imaging and bioluminescence cell viability assays, revealed that PBAs were taken up by the glioblastoma cells, with moderate biocompatibility at concentrations below the mM range.
RESUMEN
We are investigating the biological and biomedical imaging roles and impacts of fluorescent metallocorrole-TiO2 nanoconjugates as potential near-infrared optical contrast agents in vitro in cancer and normal cell lines. The TiO2 nanoconjugate labeled with the small molecule 2,17-bis(chlorosulfonyl)-5,10,15-tris(pentafluorophenyl)corrolato aluminum(III) (1-Al-TiO2) was prepared. The nanoparticle 1-Al-TiO2 was characterized by transmission electron microscopy (TEM) and integrating-sphere electronic absorption spectroscopy. TEM images of three different samples of TiO2 nanoparticles (bare, H2O2 etched, and 1-Al functionalized) showed similarity in shapes and sizes with an average diameter of 29nm for 1-Al-TiO2. Loading of 1-Al on the TiO2 surfaces was determined to be ca. 20-40mg 1-Al/g TiO2. Confocal fluorescence microscopy (CFM) studies of luciferase-transfected primary human glioblastoma U87-Luc cells treated with the nanoconjugate 1-Al-TiO2 as the contrast agent in various concentrations were performed. The CFM images revealed that 1-Al-TiO2 was found inside the cancer cells even at low doses (0.02-2µg/mL) and localized in the cytosol. Bioluminescence studies of the U87-Luc cells exposed to various amounts of 1-Al-TiO2 showed minimal cytotoxic effects even at higher doses (2-2000µg/mL) after 24h. A similar observation was made using primary mouse hepatocytes (PMH) treated with 1-Al-TiO2 at low doses (0.0003-3µg/mL). Longer incubation times (after 48 and 72h for U87-Luc) and higher doses (>20µg/mL 1-Al-TiO2 for U87-Luc and >3µg/mL 1-Al-TiO2 for PMH) showed decreased cell viability.
